PHASE I/II STUDY OF SNX-111 ADMINISTERED TO TERMINAL PATIENTS IN CHRONIC PAIN

本研究的目的是评估安全性、耐受性和 鞘内注射SNX-111剂量增加的镇痛作用 对患有慢性疼痛并有过 对阿片类药物治疗的反应不满意。 SNX-111是一种新型的 特异性阻断N型神经元特异性的钙通道阻滞剂， 突触前神经中发现的电压敏感性钙通道 terminals. 这是一项多中心研究，预计将有30例患者 其中5个将在埃默里大学学习。 两名患者被 评估。 目前正在修改方案，以便重新提交给 GAC。

The objective of this study is to asses the safety, tolerability and analgesic effects of rising doses of SNX-111, administered intrathecally to terminally ill patients who suffer from chronic pain and have had an unsatisfactory response to opioid therapy. SNX-111 is a new type of calcium channel blocker that specifically blocks N-type neuron-specific, voltage-sensitive calcium channels which are found at presynaptic nerve terminals. This is a multicenter study, where 30 patients are expected to enroll, 5 of which will be studied at Emory. Two patients have been evaluated. The protocol is currently being modified for resubmission to the GAC.